The cyclooxygenase 2-765 C promoter allele is a protective factor for Alzheimer's disease

被引:33
作者
Abdullah, L
Ait-Ghezala, G
Crawford, F
Crowell, TA
Barker, WW
Duara, R
Mullan, M
机构
[1] Roskamp Inst, Sarasota, FL USA
[2] Mt Sinai Med Ctr, Wien Ctr Alzheimers Dis & Memory Disorders, Miami Beach, FL 33140 USA
[3] Univ Miami, Miller Sch Med, Miami, FL 33152 USA
关键词
Alzheimer's disease cyclooxygenase 2; inflammation;
D O I
10.1016/j.neulet.2005.10.090
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The cyclooxygenase-2 enzyme (COX-2) is of particular importance in the inflammatory response and recent findings have demonstrated a considerable role in Alzheimer's disease (AD) pathogenesis. In order to assess the possible putative role of a COX-2 polymorphism (765 G/C) in AD, we examined its distribution in 161 community-based controls and 168 AD clinic-based cases previously recruited from memory disorder clinics in Tampa and Miami, Florida. There were no significant differences between the two groups in age/age of onset or gender. A significant difference was observed in the distribution of the COX-2-765 alleles between AD cases and controls (X-2 = 6.565, p =.010; OR =.596; Cl = [.401-.888], p =.011), with the frequency of the C allele being higher in controls. In addition, a significant difference was observed for this polymorphism by genotype (X-2 = 6.56 1, p =.038) and by presence or absence of C+ genotypes (X-2 = 6.207, p =.013; OR =.464, CI = [.351-885], p =.013). In this sample, the C allele of COX-2-765 promoter polymorphism is associated with decreased risk of Alzheimer's disease, a finding which further supports the involvement of COX-2 in AD etiology. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:240 / 243
页数:4
相关论文
共 36 条
[1]   Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists - The Cache County Study [J].
Anthony, JC ;
Breitner, JCS ;
Zandi, PP ;
Meyer, MR ;
Jurasova, I ;
Norton, MC ;
Stone, SV .
NEUROLOGY, 2000, 54 (11) :2066-2071
[2]  
Bergamaschini L, 1999, CLIN EXP IMMUNOL, V115, P526
[3]   A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen [J].
Bjarnason, I ;
Macpherson, A ;
Rotman, H ;
Schupp, J ;
Hayllar, J .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1997, 32 (02) :126-130
[4]   Results of a high-resolution genome screen of 437 Alzheimer's Disease families [J].
Blacker, D ;
Bertram, L ;
Saunders, AJ ;
Moscarillo, TJ ;
Albert, MS ;
Wiener, H ;
Perry, RT ;
Collins, JS ;
Harrell, LE ;
Go, RCP ;
Mahoney, A ;
Beaty, T ;
Fallin, MD ;
Avramopoulos, D ;
Chase, GA ;
Folstein, MF ;
McInnis, MG ;
Bassett, SS ;
Doheny, KJ ;
Pugh, EW ;
Tanzi, RE .
HUMAN MOLECULAR GENETICS, 2003, 12 (01) :23-32
[5]   Vascular involvement in cognitive decline and dementia - Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study [J].
Breteler, MMB .
VASCULAR FACTORS IN ALZHEIMER'S DISEASE, 2000, 903 :457-465
[6]   A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke [J].
Cipollone, F ;
Toniato, E ;
Martinotti, S ;
Fazia, M ;
Iezzi, A ;
Cuccurullo, C ;
Pini, B ;
Ursi, S ;
Vitullo, G ;
Averna, M ;
Arca, M ;
Montali, A ;
Campagna, F ;
Ucchino, S ;
Spigonardo, F ;
Taddei, S ;
Virdis, A ;
Ciabattoni, G ;
Notarbartolo, A ;
Cuccurullo, F ;
Mezzetti, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (18) :2221-2228
[7]  
Czyzewski K, 2001, Neurol Neurochir Pol, V35, P405
[8]  
DICKSON DW, 1988, AM J PATHOL, V132, P86
[9]   Cyclooxygenase in biology and disease [J].
Dubois, RN ;
Abramson, SB ;
Crofford, L ;
Gupta, RA ;
Simon, LS ;
Van De Putte, LBA ;
Lipsky, PE .
FASEB JOURNAL, 1998, 12 (12) :1063-1073
[10]   Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies [J].
Etminan, M ;
Gill, S ;
Samii, A .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7407) :128-+